Navigation Links
Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study
Date:5/18/2011

rmation about Nexavar including U.S. Nexavar prescribing information, visit www.nexavar.com or call 1.866.NEXAVAR (1.866.639.2827).

About Bayer HealthCare Pharmaceuticals Inc.

Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals business of Bayer HealthCare LLC, a subsidiary of Bayer AG. Bayer HealthCare is one of the world's leading, innovative companies in the healthcare and medical products industry, and combines the activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. As a specialty pharmaceutical company, Bayer HealthCare Pharmaceuticals provides products for Diagnostic Imaging, General Medicine, Hematology, Neurology, Oncology and Women's Healthcare. The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next generation proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors. ONX 0801, an alpha-folate receptor targeted inhibitor of the thymidylate synthase, and ONX 0912, an oral proteasome inhibitor, are currently in Phase 1 testing. For more information about Onyx, visit
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
2. ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar(R)
3. Nexavar First FDA-Approved Drug Therapy for Liver Cancer
4. Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
5. New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting
6. The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer
7. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
8. Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
9. Bayer and Onyx Announce Nexavar Data Presentations at 60th American Association for the Study of Liver Diseases Annual Meeting
10. Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies
11. Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Professional Compounding Centers of America (PCCA) ... the three best scientific presentations at the sixth ... The Formulating Better Medicines for Children  conference, ... Athens, Greece , includes dozens of poster-style ... which three winners will be selected by a ...
(Date:8/21/2014)... 2014   Royal Philips (NYSE: ... has received 510(k) clearance from the U.S. Food ... application for Transcatheter Aortic-Valve Implantation (TAVI) treatments. Through ... with pre-procedural, high-precision positioning to treat aortic stenosis ... is available as part of Philips IntelliSpace ...
(Date:8/21/2014)... 21, 2014  SI-BONE, Inc. ( San Jose, ... the use of the iFuse Implant System, ® ... of the sacroiliac (SI) joint, announced that Priority Health ... its Lumbar Fusion Medical Policy No. 91590-R4 providing positive ... policy states that the fusion procedure, which employs the ...
Breaking Medicine Technology:Professional Compounding Centers of America will award top poster-session winners at European Paediatric Formulation Initiative in Athens 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 3SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3
(Date:8/21/2014)... August 21, 2014 The new ... from Lockton Companies and builds on Accountable Health ... cellular glucometer, combined with Accountable Health’s robust member ... analytic capabilities and adds a custom incentive platform ... eye exams, provider visits, HbA1c testing and more. ...
(Date:8/21/2014)... 21, 2014 Relias Learning, the leader ... and human services markets, announced the latest release of ... the Tin Can API. , “Supporting the Tin ... the most advanced mobile learning capabilities and the ability ... tools and techniques,” says Jim Triandiflou, CEO of Relias ...
(Date:8/21/2014)... to be elicited by T-type calcium channels in ... regulate influxes of calcium. These channels enable thalamic ... the neurons to enter a hyper-excited state. , ... firing and absence seizures, the researchers conducted an ... gene targeting techniques to delete the T-type calcium ...
(Date:8/21/2014)... August 21, 2014 ... Peripheral Vascular Devices Market by Angioplasty ... Catheter (IVUS, OCT), IVC Filter (Retrievable), ... 2018" analyzes and studies the major ... the U.S. and Canada. , Browse ...
(Date:8/21/2014)... mynt welcomes industry leaders Rob and ... its growing company. Since its pre-launch in April, mynt ... and continues to gain momentum leading up to its ... Tiffanie came into network marketing by chance. Tiffanie worked ... network marketing companies. Tiffanie needed help at one particular ...
Breaking Medicine News(10 mins):Health News:Accountable Health Expands Diabetes Management Solutions to Address Gaps in Provider Care 2Health News:Accountable Health Expands Diabetes Management Solutions to Address Gaps in Provider Care 3Health News:Relias Learning Announces Support for Tin Can API 2Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 2Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 3Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 4Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 5Health News:Industry Leaders Rob and Tiffanie Moffitt Join mynt 2
... for cancer when they were children have a higher-than-average ... severe in the years following treatment, according to ... of the International Society of Paediatric Oncology (SIOP) in ... Cancer Center and their colleagues say their findings suggest ...
... scientists will receive grants totaling $9.35 million to help ... and traumatic brain injury. The grants from the ... 21, to Dr. Henry Klassen, Leslie M. Thompson, Brian ... Sue and Bill Gross Stem Cell Research Center at ...
... cholesterol-lowering drug reduced the enlarged prostates of hamsters to the ... prostatic hyperplasia (BPH), report researchers at Children,s Hospital Boston and ... Urology. Together, the drugs worked even better. "We don,t ... lowering cholesterol has the potential to reduce BPH in men," ...
... WHAT: Researchers funded by the National Institutes of Health have ... is evolving into two separate species with different traits, ... and potentially require new disease prevention methods. Their findings ... issue of the journal Science . A. ...
... of California, San Diego School of Medicine indicates that parent-only ... that include parents and child, while at the same time ... The results were published today in the advanced online edition ... PhD, associate professor of pediatrics and psychiatry at UC San ...
... -- If you,re a nonsmoker who lives in an apartment, ... smoke, says a new study. Researchers at Roswell Park ... 30 apartments within 11 buildings and found that secondhand smoke ... apartments of nonsmokers. The extent of the secondhand smoke ...
Cached Medicine News:Health News:Childhood cancer survivors face long-term risk of GI complications, study finds 2Health News:UCI stem cell researchers to receive $9.35 million in state funding 2Health News:UCI stem cell researchers to receive $9.35 million in state funding 3Health News:Cholesterol-lowering drug shrinks enlarged prostates in hamster model 2Health News:Parent-only treatment may be equally effective for children who are obese 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: